Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by
hypermutation leading to abundant neoantigens that activate an antitumor immune …

Simple Summary Late-stage colorectal cancer treatment often involves chemotherapy and
radiation that can cause dose-limiting toxicity, and therefore there is great interest in …

Background Colorectal cancer (CRC) is one of the most common malignant tumors in the
world. Ferroptosis is a newly defined form of cell death, distinguished by different …

The revolution of precision medicine has produced unprecedented seismic shifts in the
treatment paradigm of advanced cancers. Among the major killers, colorectal cancer (CRC) …

Cancer immunity is regulated by several mechanisms that include co-stimulatory and/or co-
inhibitory molecules known as immune checkpoints expressed by the immune cells. In …

Colorectal cancer represents the second leading cause of cancer-related death worldwide.
The therapeutic field of immuno-oncology has rapidly gained momentum, with strikingly …

The use of immune checkpoint inhibitors (ICIs) in clinical practice for the treatment of
metastatic colorectal cancer (mCRC) is currently limited to patients with deficient mismatch …

Simple Summary Microsatellite instability (MSI) is a molecular indicator of defective DNA
mismatch repair (dMMR). MSI/dMMR status is observed in approximately 5% of metastatic …

Background Immunotherapy demonstrated remarkable efficacy in metastatic colorectal
cancers (mCRCs) with mismatch repair deficiency (MMRd)/microsatellite instability (MSI) …

Colon cancer needs better screening and treatment options. Its incidence in the young
population is rising. Recent changes in guidelines recommend beginning screening for …